Published in Expert Rev Hematol on February 01, 2012
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J (2005) 2.33
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation (2003) 2.03
Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol (2013) 2.00
Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade. Eur Heart J (2007) 1.59
[Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)]. G Ital Cardiol (Rome) (2013) 1.53
Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am Heart J (2005) 1.52
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) (2009) 1.52
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Rev Esp Cardiol (Engl Ed) (2015) 1.49
Normothermia does not improve postoperative hemostasis nor does it reduce inflammatory activation in patients undergoing primary isolated coronary artery bypass. J Thorac Cardiovasc Surg (2002) 1.46
Drug-eluting stents vs. bare metal stents in saphenous vein graft disease. Insights from a meta-analysis of 7,090 patients. Circ J (2010) 1.44
Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. EuroIntervention (2016) 1.42
"Sirolimus or paclitaxel drug eluting stent in left main disease: the winner is... ". Int J Cardiol (2011) 1.41
Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients. Thromb Haemost (2015) 1.40
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 1.36
Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J (2005) 1.34
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J (2011) 1.34
Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. Ann Intern Med (2013) 1.24
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J (2011) 1.23
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost (2009) 1.21
Insulin-like growth factor-1 as a vascular protective factor. Circulation (2004) 1.21
A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol (2012) 1.13
Hypercoagulable states in cardiovascular disease. Circulation (2008) 1.09
Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis (2008) 1.07
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 0.99
Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis (2011) 0.96
Bedside monitoring of antiplatelet therapy for coronary stenting. N Engl J Med (2013) 0.95
Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol (2011) 0.92
Preoperative C-reactive protein level and outcome following coronary surgery. Eur J Cardiothorac Surg (2002) 0.91
Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. Clin Res Cardiol (2012) 0.90
Effect of α-lipoic acid on platelet reactivity in type 1 diabetic patients. Diabetes Care (2012) 0.89
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thromb Res (2012) 0.89
Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur Heart J (2005) 0.88
Leading avoidable cause of premature deaths worldwide: case for obesity. Am J Med (2013) 0.88
Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina. Circulation (2003) 0.86
Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail (2012) 0.85
[Helicobacter pylori and atherosclerosis. A review of the literature]. Recenti Prog Med (2009) 0.85
Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin (2014) 0.85
Pregnancy associated plasma protein-A and coronary atherosclerosis: marker, friend, or foe? Eur Heart J (2005) 0.85
Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol (2007) 0.85
Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J (2014) 0.84
Diurnal variation in platelet inhibition by clopidogrel. Platelets (2011) 0.84
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost (2012) 0.84
Body fat and cardiovascular risk: understanding the obesity paradox. Eur Heart J (2009) 0.84
Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery. J Thorac Cardiovasc Surg (2003) 0.84
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2016) 0.83
Reduced CD34+, renal anemia, and adverse outcomes. Am Heart J (2006) 0.82
[2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation]. Kardiol Pol (2015) 0.82
Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention (2011) 0.82
Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. Am J Cardiol (2002) 0.82
Pregnancy-associated plasma protein-A and acute coronary syndromes: cause or consequence? J Am Coll Cardiol (2005) 0.81
4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study. J Thromb Thrombolysis (2003) 0.81
Predictors of exercise-induced platelet reactivity in patients with chronic stable angina. J Cardiovasc Med (Hagerstown) (2009) 0.81
Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology. Cardiol J (2011) 0.80
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety. Circulation (2013) 0.80
Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction. Mediators Inflamm (2012) 0.80
Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. Atherosclerosis (2011) 0.80
ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-of-hospital cardiac arrest survivors improves clinical outcomes: the first European experience. Scand J Trauma Resusc Emerg Med (2013) 0.80
Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. Eur J Clin Invest (2011) 0.80
Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res (2012) 0.80
Lost and found: an unusual late complication of the Angio-Seal closure device. Int J Cardiol (2007) 0.80
Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction. Int J Cardiol (2009) 0.79
Prediction of high risk of non-adherence to antiplatelet treatment. Kardiol Pol (2015) 0.78
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study. J Cardiovasc Med (Hagerstown) (2009) 0.78
Increased platelet reactivity in unstable angina patients is not related to C-reactive protein levels. Platelets (2006) 0.78
Relation between nitric oxide metabolites and haemoglobin concentrations in patients with ischaemic heart disease. Heart (2007) 0.78
Heart-kidney interactions in ischemic syndromes. Circulation (2004) 0.77
Testosterone, tissue factor inhibition and vascular aging. Thromb Haemost (2009) 0.77
Inflammation, genetics, and ischemic heart disease: focus on the major histocompatibility complex (MHC) genes. Cytokine (2004) 0.77
Interplay of platelet polymorphisms, risk factors, and von [corrected] Willebrand factor [corrected] in determining collagen-adenosine diphosphate PFA-100 results in patients with coronary artery disease. Blood Coagul Fibrinolysis (2005) 0.77
Role of PAPP-A in atherothrombosis: messages to take home. Atherosclerosis (2008) 0.77
Pregnancy-associated plasma protein a as predictor of outcome in patients with suspected acute coronary syndromes. Circulation (2004) 0.77
[2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. G Ital Cardiol (Rome) (2016) 0.76
Unraveling Reaven's syndrome X: serum insulin-like growth factor-I and cardiovascular disease. Circulation (2003) 0.76
Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions. Curr Med Res Opin (2011) 0.76
Polycythemia, vascular function, and hemoglobin-nitric oxide reactions. J Appl Physiol (1985) (2011) 0.75
Regarding "a closer look at meta-analyses of observational data". J Vasc Surg (2010) 0.75
Procedure volume and outcome: you should take into account each hospital. J Am Coll Cardiol (2011) 0.75
IgA anticardiolipin antibody is associated with the extent of daily-life ischaemia in patients with chronic coronary artery disease. Heart (2007) 0.75
Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor. Thromb Haemost (2008) 0.75
The unstable plaque: a broken balance. Eur Heart J (2009) 0.75
"Meta-analysis of ablation of atrial flutter and supraventricular tachycardia". Am J Cardiol (2010) 0.75
Hemoglobin levels, nitric oxide bioavailability and cardiovascular outcomes. Am J Cardiol (2011) 0.75
Substandard life-saving drugs: a global concern. Eur Heart J (2005) 0.75
Effectiveness and safety of drug-eluting stents in vein grafts: a meta-analysis. Am Heart J (2010) 0.75